Yingzhong Li
President SunVax mRNA Therapeutics
Yingzhong Li earned his Ph.D. on Biotechnology from Peking University & National Institute of Biological Sciences, Beijing, China in 2010. Dr. Li got further trainings on multiple disciplines and interdisciplinary at MIT. Currently Dr. Li holds 6 PCT patents at MIT and 5 PCT patents at SunVax mRNA Therapeutics in the field of cancer immunology and mRNA techniques. Dr. Li is President of SunVax mRNA Therapeutics Inc. after left MIT in the end of 2021.
Seminars
Wednesday 27th May 2026
Panel: Comparing Delivery Architectures to Match Modalities to Indication Needs
4:45 pm
- Debate core trade-offs including tropism, immunogenicity, manufacturability, payload size, and dosing frequency across LNP, AAV, and novel options
- Determine best-fit delivery platforms for CNS, immune modulation, oncology, hepatic, and neuromuscular indications
- Address LNP partnership models that support predictable GMP supply and scalable therapeutic development
Thursday 28th May 2026
Harnessing Cascade Amplification & Therapeutic Payload (CATP) Systems to Unlock Potent, Low-Dose & Multi-Payload saRNA Therapeutics
11:00 am
- Achieve strong therapeutic expression at lower doses using a two-step amplification system that combines saRNA with defective viral replication to bypass current safety– efficacy limits
- Enable multi-gene and complex therapeutic logic through a dual-amplification system capable of supporting larger and more sophisticated payloads beyond traditional vaccine applications
- Improve targeting precision and reduce off-target liver accumulation with advanced delivery design that supports tissue- and cell-type–specific uptake for safer, more predictable translation
